S
Stefan Schäfer
Researcher at Bayer Corporation
Publications - 33
Citations - 673
Stefan Schäfer is an academic researcher from Bayer Corporation. The author has contributed to research in topics: Diabetic nephropathy & Pulmonary hypertension. The author has an hindex of 15, co-authored 31 publications receiving 631 citations. Previous affiliations of Stefan Schäfer include Aventis Pharma.
Papers
More filters
Journal ArticleDOI
Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling
Martina Klein,Ralph T. Schermuly,Peter Ellinghaus,Hendrik Milting,Bernd Riedl,Sevdalina Nikolova,Soni Savai Pullamsetti,Norbert Weissmann,Eva Dony,Rajkumar Savai,Hossein Ardeschir Ghofrani,Friedrich Grimminger,Andreas Busch,Stefan Schäfer +13 more
TL;DR: The multikinase inhibitor sorafenib prevents pulmonary remodeling and improves cardiac and pulmonary function in experimental pulmonary hypertension and may provide an option to treat pulmonary arterial hypertension and associated right heart remodeling.
Journal ArticleDOI
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.
Stefan Schäfer,Wolfgang Linz,Axel Bube,Martin Gerl,Jochen Huber,Gert Ulrich Kürzel,Markus Bleich,Hans-Ludwig Schmidts,Andreas E. Busch,Hartmut Rütten +9 more
TL;DR: In ZDF rats, development of diabetes mellitus is accompanied by functional and morphological kidney damage that resembles human diabetic nephropathy and can be prevented by chronic vasopeptidase inhibition, which can reduce the incidence and severity of glomerulosclerosis and tubulointerstitial damage.
Journal ArticleDOI
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
Franz von Nussbaum,Volkhart Min-Jian Li,Swen Allerheiligen,Sonja Anlauf,Lars Bärfacker,Martin Bechem,Martina Delbeck,Fitzgerald Mary F,Michael Gerisch,Heike Gielen-Haertwig,Helmut Haning,Dagmar Karthaus,Dieter Lang,Klemens Lustig,Daniel Meibom,Joachim Mittendorf,Ulrich Rosentreter,Martina Schäfer,Stefan Schäfer,Jens Schamberger,Leila Telan,Adrian Tersteegen +21 more
TL;DR: A novel dihydropyrimidinone lead‐structure class was identified and was shown to be efficacious in a rodent animal model related to ALI, and is currently being tested in clinical studies for the treatment of pulmonary diseases.
Journal ArticleDOI
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Cornelia Wihler,Stefan Schäfer,K. Schmid,E. K. Deemer,Gerald Münch,Markus Bleich,Markus Bleich,Andreas E. Busch,T. Dingermann,Veronika Somoza,John W. Baynes,Jochen Huber +11 more
TL;DR: Improved AGE clearance and direct inhibition of AGE formation by chelation may contribute to reduced accumulation of renal AGEs and to the nephroprotective effects of vasopeptidase inhibition in type 2 diabetes.
Journal ArticleDOI
Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine.
TL;DR: This work investigated whether accumulation of advanced glycation end products in the diabetic myocardium is related to its functional abnormalities and found that it is not.